611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Small World? Not With One-Quarter Obese by 2045IBD Associated With Increased Risk of Parkinson's DiseaseBlue's Clues: Adding Dye to Colonoscopy May Boost DetectionHealth Concerns Rise Along With Hawaii EruptionsFDA OKs Doptelet for Liver Dz Patients Undergoing ProceduresEven a Mosquito's Spit May Help Make You SickFDA Approves Aimovig to Prevent MigrainesLower Vitamin D levels Linked to More Belly FatCan the Mediterranean Diet Protect Against Smog-Related Deaths?Many Parents Say Restaurant Fare Has Made Kids Sick: PollVarious Clinical Disturbances Precede MS DiagnosisFDA Approves First Drug Aimed at Preventing MigrainesAcute Kidney Injury in Hospital Ups Risk of Later Heart FailurePools, Hot Tubs Can Harbor Dangerous GermsAHA: 'Ideal' Heart Health Eludes More AmericansOrgans From Opioid OD Victims Are Saving Lives: StudyMore Cases in Lettuce-Linked E. Coli Outbreak, But End May Be NearFremanezumab Linked to Fewer Monthly Migraine DaysNew Rabies Test Could Save Lives, Maybe Even Minus the ShotsHealth Tip: Understanding Childhood ArthritisFDA Approves 'Biosimilar' Drug to Treat Certain Types of AnemiaColon Polyp Type May Be Key to Cancer Risk'BioSimilar' Drug Approved to Treat Certain Types of AnemiaHealth Tip: Taming a Pollen AllergyHealth Tip: Identifying Asthma Triggers'Superbug' Surfaces at Poultry Farm in ChinaSun's UV Rays a Threat to Your Eyes, TooMalnutrition Is Associated With Poor Prognosis in Heart FailureAntibiotics Tied to Higher Kidney Stone RiskMore Doubt Cast on Surgery for Spinal Compression FracturesObesity Might Raise Your Risk for A-fibAffected by the EpiPen Shortage? Here's What to DoIs Testing for Zika in U.S. Blood Supply Worth the Cost?FDA Permits Marketing of New Device for Treating GI BleedingPTSD May Raise Odds for Irregular HeartbeatNew Device Cleared for Gastrointestinal BleedingIf Kids Exposed to Pot, Tobacco Smoke, ER Visits RiseEven Mild Concussion Tied to Greater Dementia Risk LaterHealth Tip: Help Prevent E coli InfectionCBD Oil: All the Rage, But Is It Really Safe and Effective?Low Neighborhood Walkability Increases Risk of Asthma in KidsSleep-Deprived Kids at Risk of ObesityStudy IDs Pain Descriptors for Varying Stages of Low Back PainHealth Tip: Prepare for a ColonoscopyFurther Signs That Too Much Sitting Can Raise Clot RiskLightning Can Affect Deep Brain Stimulation DevicesThe Cold Truth About Migraine HeadachesHealth Tip: When To Call Your Doctor If You Have Lower Back PainSkin's 'Good' Bacteria May Be Promising Weapon Against EczemaFirst Death Reported in E. Coli Outbreak Tied to Romaine Lettuce
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Serum Caffeine, Metabolites May Predict Early Parkinson's Disease


HealthDay News
Updated: Jan 3rd 2018

new article illustration

WEDNESDAY, Jan. 3, 2018 (HealthDay News) -- Serum levels of caffeine and its metabolites could be diagnostic biomarkers for early Parkinson's disease (PD), according to a study published online Jan. 3 in Neurology.

Motoki Fujimaki, M.D., from the Juntendo University School of Medicine in Tokyo, and colleagues examined the kinetics and metabolism of caffeine in serum from 108 patients with PD and 31 age-matched healthy controls. Levels of caffeine and its 11 metabolites were examined by liquid chromatography-mass spectrometry. Direct sequencing was conducted to screen for mutations in caffeine-associated genes.

The researchers observed significant decreases in serum levels of caffeine and nine of its downstream metabolites, even in patients with early PD, which were unrelated to total caffeine intake or severity of disease. Compared with controls, there were no significant variations in CYP1A2 or CYP2E1, encoding cytochrome P450 enzymes involved in metabolizing caffeine. Patients with PD with motor complications had significantly decreased caffeine concentrations compared to PD patients without motor complications. There were no correlations between disease severity and single nucleotide variants of the ADORA2A gene encoding adenosine 2A receptor. In receiver operating characteristic curve analysis, the profile of serum caffeine and metabolite levels was identified as a potential diagnostic biomarker.

"Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD," the authors write. "This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies."

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)